Curanex (NASDAQ: CRNX) Expands Pipeline to Target Cancer Cachexia
Market Overview Curanex (NASDAQ: CRNX) is broadening its strategic focus by advancing its drug development pipeline into cancer cachexia, a critical and underserved area within oncology supportive care. This pivot taps into a multi-billion-dollar market opportunity as the demand for effective treatments addressing this severe condition—characterized by weight loss and muscle wasting among cancer patients—is growing rapidly. The company’s stock has drawn attention from investors anticipating growth fueled by this…
